_śXg
1. Kinoshita, T., Imamura, R.,
Kushiyama, H., and Suda, T.: NLRP3 mediates NF-ČB activation and cytokine induction in
microbially induced and sterile inflammation. PLoS
One. 2015, 10(3):e0119179
2. Wang, Q., Imamura, R., Motani, K.,
Kushiyama, H., Nagata,
S., and Suda, T. Pyroptotic cells externalize eat-me and release find-me
signals and are efficiently engulfed by macrophages. Int. Immunol. 2013,
25(6):363-372.
3. Harashima, N., Inao, T., Imamura, R.,
Okano, S., Suda, T., and Harada, M.: Roles of the PI3K/Akt pathway and autophagy in TLR3 signaling-induced
apoptosis and growth arrest of human prostate cancer cells. Cancer
Immunol. Immunother. 2012, 61(5):667-676
4. Motani, K.,
Kushiyama, H., Imamura, R., Kinoshita, T., Nishiuchi, T., and Suda, T.: Caspase-1 protein induces
apoptosis-associated speck-like protein containing a caspase recruitment domain
(ASC)-mediated necrosis independently of its catalytic activity. J. Biol. Chem. 2011,
286(39):33963-33972
5. Motani, K., Kawase, K., Imamura, R.,
Kinoshita, T., Kushiyama, H., and Suda, T.: Activation of ASC induces apoptosis
or necrosis, depending on the cell type, and causes tumor eradication. Cancer Sci. 2010. 101(8):1822-1827
6. Imamura, R., Wang, Y., Kinoshita, T.,
Suzuki, M., Noda, T., Sagara, J., Taniguchi, S., Okamoto, H., and Suda, T.: Anti-inflammatory
activity of PYNOD and its mechanism in humans and mice. J. Immunol. 2010.
184(10):5874-5884.
7. Hasegawa,
M., Imamura, R., Motani, K., Nishiuchi, T., Matsumoto, N., Kinoshita, T., and
Suda, T.: Mechanism and repertoire of ASC-mediated gene expression. J. Immunol. 2009, 182(12):7655-7662
8. Ohno, S.,@Kinoshita, T., Ohno, Y.,
Minamoto, T., Suzuki N., Inoue M., and Suda, T.: Expression of NLRP7 (PYPAF3,
NALP7)Protein in Endometrial Cancer Tissues. Anticancer Res. 2008. 28(4C):2493-2497.
9.
Matsumoto,
N., Imamura, R., Suda, T.: Caspase-8- and JNK-dependent AP-1 activation is
required for Fas ligand-induced IL-8 production. FEBS
J. 2007/5, 274(9):2376-2384
10. Umemura, M., Yahagi, A., Hamada, S.,
Begum, M. D., Watanabe, H., Kawakami, K., Suda, T., Sudo, K., Nakae, S.,
Iwakura, Y., and Matsuzaki, G.: IL-17-mediated regulation of innate and
acquired immune response against pulmonary Mycobacterium bovis BCG
infection, J.
Immunol., 2007/3, 178(6):3786-3796.
11. Fujisawa, A., Kambe, N., Saito, M.,
Nishikomori, R., Tanizaki, H., Kanazawa, N., Adachi, S., Heike, T., Sagara, J.,
Suda, T., Nakahata, T., Miyachi, Y.: Disease-associated mutations in CIAS1
induce cathepsin B-dependent rapid cell death of human THP-1 monocytic cells, Blood,
2007/4, 109(7):2903-2911.
12. Kinoshita, T.,
Kondoh, C., Hasegawa, M., Imamura, R., and Suda, T.: Fas-associated Factor 1 is
a negative regulator of PYRIN-containing Apaf-1-like protein 1, Int.
Immunol., 2006, 18:1701-1706.
13. El Kasmi, K.C.,
Holst J, Coffre, M., Mielke, L., de Pauw, A., Lhocine, N., Smith, A.M.,
Rutschman, R., Kaushal, D., Shen, Y., Suda, T., Donnelly, R.P., Myers, M.G.
Jr., Alexander, W., Vignali, D.A., Watowich, S.S., Ernst, M., Hilton, D.J.,
Murray, P.J.: General nature of the STAT3-activated anti-inflammatory response.
J.
Immunol., 2006, 177:7880-7888.
14.
Hasegawa, M., Kawase, K., Inohara, N., Imamura, R., Yeh,
W-C.,Kinoshita, T., and Suda, T.: Mechanism of
ASC-mediatedapoptosis: Bid-dependent apoptosis in type II cells, Oncogene,
2006, In press.
15.
Kidoya,
H., Umemura, U., Kawabe, T.,Matsuzaki, G., Yahagi, A., Imamura, R., and Suda,
T. (2005) Fas ligand inducescell-autonomous IL-23 production in dendritic
cells, a mechanism for Fasligand-induced IL-17 production. J. Immunol.175:8024-31. [PubMed]
16. Kinoshita,T., Wang, Y.,
Hasegawa, M., Imamura, R., and Suda, T. (2005) PYPAF3, aPYRIN-containing
APAF-1-like protein, is a feedback regulator ofcaspase-1-dependent
interleukin-1b secretion. J. Biol. Chem. 280:21720-5[PubMed]
17. Hasegawa M,Imamura R, Kinoshita T,
Matsumoto N, Masumoto J, Inohara N, and Suda T. (2005)ASC-mediated NF-kB activation leading to interleukin-8
productionrequires caspase-8 and is inhibited by CLARP. J. Biol. Chem. 280: 15122-30. [PubMed]
18. Imamura, R.,Konaka, K., Matsumoto,
N., Hasegawa, M., Fukui, M., Mukaida, N., Kinoshita,
T., and Suda, T. (2004) Fas ligandinduces cell-autonomous NF-kB activation and IL-8 production by a
mechanismdistinct from that of TNF-a. J. Biol. Chem.279:46415-23. [PubMed]
19. Umemura, M.,Kawabe, T., Shudo, K.,
Kidoya, H., Fukui, M., Asano, M., Iwakura, Y.,Matsuzaki, G., Imamura, R., and
Suda, T. (2004) Involvement of IL-17 in Fasligand-induced inflammation. Int.
Immunol. 16:1099-108.[PubMed]
20. Wang, Y.,Hasegawa, M., Imamura, R.,
Kinoshita, T., Kondo, C., Konaka, K., Suda, T.(2004) PYNOD, a novel
Apaf-1/CED4-like protein is an inhibitor of ASC andcaspase-1. Int. Immunol. 16:777-86. [PubMed]
21. Nakamoto Y, SudaT, Momoi T, and
Kaneko S. (2004) Different procarcinogenic potentials oflymphocyte subsets in a
transgenic mouse model of chronic hepatitis B. CancerRes. 64:3326-3333 [PubMed]
22. Fukui, M.,Imamura, R., Umemura, M.,
Kawabe, T., Suda, T. (2003) Pathogen-associatedmolecular patterns sensitize
macrophages to Fas ligand-induced apoptosis andIL-1beta release. J. Immunol..
171:1868-74. [PubMed]
23. Tachiiri,A., Imamura, R., Wang, Y.,
Fukui, M., Umemura, M., and Suda, T. (2003) Genomicstructure and inducible
expression of the IL-22 receptor a chain in mice. Gene. Immun.,
4:153-159 [PubMed]
24. Nakamoto, Y.Kaneko, S., Fan, H.,
Momoi, T., Tsutsui, H., Nakanishi, K., Kobayashi, K., andSuda, T. (2002)
Prevention of Hepatocellular Carcinoma Development Associatedwith Chronic
Hepatitis by Anti-Fas Ligand Antibody Therapy. J. Exp. Med.,196:1105-1111 [PubMed]
25. Fukuyama H,Adachi M, Suematsu S, Miwa
K, Suda T, Yoshida N, Nagata S. (2002) Requirementof Fas expression in B cells
for tolerance induction. Eur. J. Immunol.32:223-30. [PubMed]
26. Shudo, K.,Kinoshita, K., Imamura, R.,
Fan, H., Hasumoto, K., Tanaka, M., Nagata, S., andSuda, T. (2001) The
membrane-bound but not the soluble form of human Fas ligandis responsible for
its inflammatory activity. Eur. J.Immunol.,
31:2504-2511 [PubMed]
27. Miwa, K,Hashimoto, H., Yatomi, T., Nakamura,
N., Nagata, S., and Suda, T. (1999)Therapeutic effect of an anti-Fas ligand mAb
on lethal graft-versus- hostdisease. Int Immunol 11:925-931 [PubMed]
28. Saito, I.,Haruta, K., Shimuta, M.,
Inoue, H. Sakurai, H., Yamada, K., Ishimaru, N.,Higashiyama, H., Sumida, T.,
Ishida, H., Suda, T., Noda, T., Hayashi, Y., andTsubota, K. (1999) Fas
ligand-mediated exocrinopathy resembling Sjogren'ssyndrome in mice transgenic
for IL-10. J Immunol 162:2488-2494 [PubMed]
29. Kuwano, K.,Hagimoto, N., Kawasaki,
M., Yatomi, T., Nakamura, N., Nagata, S., Suda, T.,Kunitake, R., Maeyama, T.,
Miyazaki, H., and Hara, N. (1999) Essential roles of
the Fas-Fas ligand pathway in thedevelopment of pulmonary fibrosis. J Clin
Invest 104:13-19 [PubMed]
30. Miwa, K.,Asano, M., Horai, R.,
Iwakura, Y., Nagata, S., and Suda. T. (1998) Caspase1-independent IL-1beta
release and inflammation induced by the apoptosis inducerFas ligand. Nat. Med.
4:1287-92. [PubMed]
31. Fukuyama,H., Adachi, M., Suematsu,
S., Miwa, K., Suda, T., Yoshida, N., and Nagata, S.(1998) Transgenic expression
of Fas in T cells blocks lymphoproliferation butnot autoimmune disease in
MRL-lpr mice. J Immunol 160:3805-3811. [PubMed]
32. Hashimoto,H., Tanaka, M., Suda, T.,
Tomita, T., Hayashida, K., Takeuchi, E., Kaneko, M.,Takano, H., Nagata, S., and
Ochi, T. (1998) Soluble Fas ligand in the joints ofpatients with rheumatoid
arthritis and osteoarthritis. Arthritis Rheum41:657-662. [PubMed]
33. Suda, T., Hashimoto,H., Tanaka, M.,
Ochi, T., and Nagata, S. (1997) Membrane Fas ligand kills humanperipheral blood
T lymphocytes, and soluble Fas ligand blocks the killing. J.Exp. Med.
186:2045-2050. [PubMed]
34. Hueber, A.O., Zornig, M., Lyon, D.,
Suda, T., Nagata, S., and Evan, G. I. (1997)Requirement for the CD95
receptor-ligand pathway in c-Myc-induced apoptosis.Science 278:1305-1309.
35. Tsutsui, T.,Mu, J., Ogawa, M., Yu,
W., Suda, T., Nagata,
S., Saji, F., Murata, Y., Fujiwara, H., Hamaoka, T.(1997) Administration of IL-12
induces a CD3+CD4-CD8-B220+ lymphoidpopulation capable of eliciting cytolysis
against Fas-positive tumorcells. J. Immunol. 159:2599-2605.
36. Kondo, T., Suda,T., Fukuyama, H.,
Adachi, M., and Nagata, S. (1997) Essential roles of the Fasligand in the
development of hepatitis. Nature Med. 3:409-413. [PubMed]
37. Tanaka, M.,Suda,
T., Yatomi, T., Nakamura, N., and Nagata, S. (1997). Lethal effect ofrecombinant human Fas ligand in
mice pretreated with propionibacterium acnes.J. Immunol. 158:2303-2309 [PubMed]
38. Adachi, M.,Suemura, S., Suda, T.,
Watanabe, D., Fukuyama, H., Ogasawara, J., Tanaka, T.,Yoshida, N., and Nagata,
S. (1996). Enhanced and accelerated lymphoproliferationin Fas-null mice. Proc.
Natl. Acad. Sci. 96:2131-2136. [PubMed]
39. Tanaka, M., Suda,T., Haze, K.,
Nakamura, N., Sato, K., Kimura, F., Motoyoshi, K., Mizuki, M.,Tagawa, S., Ohga,
S., Hatake, K., Drummond, A. H. and Nagata, S. (1996). Fasligand in human
serum. Nature Med. 2:317- 322. [PubMed]
40. Suda, T.,Tanaka,
M., Miwa, K., and Nagata, S. (1996). Apoptosis of mouse naive T cellsinduced by recombinant soluble Fas
ligand and activation-induced resistance toFas ligand. J. Immunol.
157:3918-3924. [PubMed]
41. Estaquier, J., Tanaka, M., Suda, T., Nagata,
S.,Golstein, P., and Ameisen, J.C. (1996). Fas-mediated apoptosis of CD4+ and
CD8+T cells from human immunodeficiency virus-infected persons: differential
invitro preventive effect of cytokines and protease antagonists.
Blood.87:4959-4966.
42. Takahashi,T., Tanaka, M., Ogasawara,
J., Suda, T., Murakami, H., Nagata, S. (1996).Swapping between Fas and
granulocyte colony-stimulating factor receptor. J.Biol. Chem. 271:17555-17560. [PubMed]
43. Yamashita,Y., Miyake, K., Miura, Y.,
Kaneko, Y., Yagita, H., Suda, T., Nagata, S.,Nomura, J., Sakaguchi, N., Kimoto,
M. (1996). Activation Mediated by RP105 butnot CD40 makes normal B cells
susceptible to anti-IgM-induced apoptosis: a rolefor Fc receptor co-ligation.
J. Exp Med. 184:113-120.
44. Nishio, A.,Katakai, T., Oshima, C.,
Kasakura, S., Sakai, M., Yonehara, S., Suda, T.,Nagata, S., and Masuda, T.
(1996). A possible involvement of Fas-Fas ligandsignaling in the pathogenesis
of murine autoimmune gastritis. Gastroenterology111:959-967.
45. Ogasawara,J., Suda,
T., and Nagata, S. (1995). Selective
apoptosis of CD4+CD8+ thymocytesby the anti-Fas antibody. J. Exp. Med.
181:485-491. [PubMed]
46. Tanaka, M.,Suda,
T., Takahashi, T., and Nagata, S. (1995). Expression of the functionalsoluble form of
human Fas ligand in activated lymphocytes. EMBO J.14:1129-1135. [PubMed]
47. Watanabe,D., Suda, T. and Nagata, S. (1995).
Expression of Fas in B cells of the mousegerminal center and Fas-dependent
killing of activated B cells. Int. Immunol.7:1949-1956. [PubMed]
48. Suda, T.,Okazaki,
T., Naito, Y., Yokota, T., Arai, N., Ozaki, S., Nakao, K., and Nagata,S.
(1995). Expression of
the Fas ligand in cells of T-cell-lineage. J. Immunol.154:3806-3813. [PubMed]
49. Watanabe,D., Suda, T., Hashimoto, H.,
and Nagata, S. (1995). Constitutive activation ofthe Fas ligand gene in mouse
lymphoproliferative disorders. EMBO J. 14:12-18. [PubMed]
50. Suda, T.,and Nagata, S. (1994).
Purification and characterization of the Fas-ligand thatinduces apoptosis. J.
Exp. Med. 179:873-878. [PubMed]
51. Takahashi,T., Tanaka, M., Brannan,
C.I., Jenkins, N.A., Copeland, N.G., Suda, T., andNagata, S. (1994).
Generalized lymphoproliferative disease in mice, caused by apoint mutation in
the Fas ligand. Cell. 76:969-976. [PubMed]
52. Takahashi,
T.,Tanaka, M., Inazawa, J., Abe, T., Suda, T., and Nagata, S. (1994). Human Fasligand; gene structure,
chromosomal location and species specificity. Int.Immunol. 6:1567-1574. [PubMed]
53. Suda, T.,Takahashi, T., Golstein, P.,
and Nagata, S. (1993). Molecular cloning andexpression of the Fas ligand: a
novel member of the tumor necrosis factorfamily. Cell. 75:1169-1178. [PubMed]
54. Ogasawara,J., Watanabe, F.R., Adachi,
M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh,N., Suda, T., and Nagata, S.
(1993). Lethal effect of the anti-Fas antibody inmice. Nature. 364:806-809. [PubMed]
55. Suda, T. andZlotnik, A. (1993).
Origin, differentiation, and repertoire selection ofCD3+CD4-CD8- thymocytes
bearing either ab or gd T cell receptors. J. Immunol. 150:447-455.
56. Godfrey,D.I., Kennedy, J., Suda, T.,
and Zlotnik, A. (1993). A developmental pathwayinvolving four phenotypically
and functionally distinct subsets of CD3-CD4-CD8-triple-negative adult mouse
thymocytes defined by CD44 and CD25 expression. J.Immunol. 150:4244-4252.
57. Godfrey,D.I., Zlotnik, A., and Suda,
T. (1992). Phenotypic and functionalcharacterization of c-kit expression during
intrathymic T cell development. J.Immunol. 149:2281-2285.
58. Suda, T. andZlotnik, A. (1992). In
vitro induction of CD8 expression on thymic pre-T cells.II. Characterization of
CD3-CD4-CD8a+ cells generated in vitro by
culturingCD25+CD3-CD4-CD8- thymocytes with T cell growth factor-b and tumor
necrosisfactor-a. J. Immunol. 149:71-76.
59. Shimizu, J.,Suda, T., Katagiri, T.,
Fujiwara, H., and Hamaoka, T. (1992). Tumor-specific Tcell lines: capacity to
proliferate and produce interleukin 2 in response tovarious forms of tumor
antigens. Jpn. J. Cancer Res. 83:184-193.
60. Zlotnik, A.,Godfrey, D.I., Fischer,
M., and Suda, T. (1992). Cytokine production by matureand immature CD4-CD8- T
cells. ab-T cell receptor+ CD4-CD8- T cells
produceIL-4. J. Immunol. 149:1211-1215.
61. Suda, T. andZlotnik, A. (1992). In
vitro induction of CD8 expression on thymic pre-T cells.I. Transforming growth
factor-b and tumor necrosis factor-a induce CD8 expression on CD8- thymicsubsets
including the CD25+CD3-CD4-CD8- pre-T cell subset. J. Immunol.148:1737-1745.
62. Suda, T. andZlotnik, A. (1991). IL-7
maintains the T cell precursor potential ofCD3-CD4-CD8- thymocytes. J. Immunol.
146:3068-3073.
63. Fischer, M.,MacNeil, I., Suda, T.,
Cupp, J.E., Shortman, K., and Zlotnik, A. (1991).Cytokine production by mature
and immature thymocytes. J. Immunol.146:3452-3456.
64. Suda, T.,Murray, R., Guidos, C., and
Zlotnik, A. (1990). Growth-promoting activity ofIL-1a, IL-6, andtumor necrosis factor-a in combination with IL-2, IL-4, or IL-7 on
murinethymocytes. Differential effects on CD4/CD8 subsets and on
CD3+/CD3-double-negative thymocytes. J. Immunol. 144:3039-3045.
65. MacNeil,I.A., Suda, T., Moore, K.W.,
Mosmann, T.R., and Zlotnik, A. (1990). IL-10, anovel growth cofactor for mature
and immature T cells. J. Immunol.145:4167-4173.
66. Suda, T.,Murray, R., Fischer, M.,
Yokota, T., and Zlotnik, A. (1990). Tumor necrosisfactor-a and P40induce day 15 murine fetal thymocyte
proliferation in combination with IL-2. J.Immunol. 144:1783-1787.
67. Suda, T.,O'Garra, A., MacNeil, I.,
Fischer, M., Bond, M.W., and Zlotnik, A. (1990).Identification of a novel
thymocyte growth-promoting factor derived from B celllymphomas. Cell. Immunol.
129:228-240.
68. Murray, R.,Suda, T., Wrighton, N.,
Lee, F., and Zlotnik, A. (1989). IL-7 is a growth andmaintenance factor for
mature and immature thymocyte subsets. Int. Immunol.1:526-531.
69. Shimizu, J.,Suda, T., Yoshioka, T.,
Kosugi, A., Fujiwara, H., and Hamaoka, T. (1989).Induction of tumor-specific in
vivo protective immunity by immunization with tumorantigen-pulsed
antigen-presenting cells. J. Immunol. 142:1053-1059.
70. Suda, T.,Hodgkin, P., Lee, F., and
Zlotnik, A. (1989). Biological activity ofrecombinant murine interleukin-6 in
interleukin-1 T cell assays. J. Immunol.Methods. 120:173-178.
71. Suda, T.,Shimizu, J., Muramatsu, M.,
Kimura, K., Yoshida, T.O., Fukami, Y., Fujiwara,H., and Hamaoka, T. (1989). The
tumor rejection antigen separated from Roussarcoma virus-induced murine
fibrosarcoma exhibits a molecular weight ofapproximately 60 kD but differs from
functional pp60src. Jpn. J. Cancer Res.80:879-886.
72. Sato, S.,Qian, J.H., Kokudo, S.,
Ikegami, R., Suda, T., Hamaoka, T., and Fujiwara, H.(1988). Studies on the
induction of tolerance to alloantigens. III. Inductionof antibodies directed
against alloantigen-specific delayed-typehypersensitivity T cells by a single
injection of allogeneic lymphocytes viaportal venous route. J. Immunol.
140:717-722.
73. Suda, T.,Sano, S., Hori, S., Azuma,
T., Tateishi, N., Hamaoka, T., and Fujiwara, H.(1988). Prevention of
suppression of alloreactive capacity followingintravenous injection of
neuraminidase-treated allogeneic cells by co-injectionof agents competing for asialoglycoprotein
receptor. Reg. Immunol. 1:24-31.
74. Suda, T.,Shimizu, J., Mizushima, Y.,
Fujiwara, H., and Hamaoka, T. (1988). Separation ofthe tumor rejection antigen
of Rous sarcoma virus-induced murine fibrosarcoma.Jpn. J. Cancer Res.
79:365-374.
75. Sano, S.,Suda, T., Qian, J.H., Sato,
S., Ikegami, R., Hamaoka, T., and Fujiwara, H.(1987). Abrogation of the
capacity of delayed-type hypersensitivity responses toalloantigens by
intravenous injection of neuraminidase-treated allogeneiccells. J. Immunol. 139:3652-3659.
76. Kosugi, A.,Yoshioka, T., Suda, T.,
Sano, H., Takahama, Y., Fujiwara, H., and Hamaoka, T.(1987). The activation of
L3T4+ helper T cells assisting the generation ofanti-tumor Lyt-2+ cytotoxic T
lymphocytes: requirement of Ia-positiveantigen-presenting cells for processing
and presentation of tumor antigens. J.Leukoc. Biol. 42:632-641.
77. Suda, T.,Fujiwara, H., Mizushima, Y.,
Shearer, G.M., and Hamaoka, T. (1986). Role ofTNP-reactive helper T cells in
augmenting anti-tumor immune response: Enhancedinduction of tumor-specific
Lyt-1+2- T cell-mediated delayed-typehypersensitivity from spleen cells of
tumor-bearing mice by TNP-helpers. J. Natl.Cancer Inst. 77:1267-1272.
78. Ohta, A.,Suda. T., Kiyono, K., and
Shibuya, I. (1986). Over production of proteinsencoded by l replicon-integrated
plasmid: Effect of partial inactivation of cIrepressor. Plasmid. 15:159-162.
79. Fujiwara,H., Moriyama, Y., Suda, T.,
Tsuchida, T., Shearer, G.M., and Hamaoka, T.(1984). Enhanced TNP-reactive
helper T cell activity and its utilization in theinduction of amplified tumor
immunity which results in tumor regression. J.Immunol. 132:1571-1577.
80. Ćuǧ䤪ěz[Ö